BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer

NCT00054314 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: ortataxel

Sponsor

Roswell Park Cancer Institute